Eli Lilly and Co (LLY.N)
|Market Cap (Mil.):||$71,898.79|
|Shares Outstanding (Mil.):||1,117.31|
- Eli Lilly and Co said its quarterly earnings plunged 58 percent, hurt by special charges and generic competition for its Cymbalta depression drug, but it affirmed its full-year profit forecast.
BAD VILBEL Germany - Germany's Stada plans to bring a copy of Eli Lilly's Forteo osteoporosis treatment to market, its chief executive said, as the generic drugmaker moves further into the sale of cheaper alternatives for costly biotech drugs.
BRUSSELS, Oct 3 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
BRUSSELS - EU antitrust regulators approved U.S. drugmaker Eli Lilly's $5.4 billion takeover of Swiss peer Novartis's animal health business on Friday.
BRUSSELS, Oct 3 - EU antitrust regulators approved U.S. drugmaker Eli Lilly's $5.4 billion takeover of Swiss peer Novartis's animal health business on Friday.
BRUSSELS - EU antitrust regulators will open an extensive probe into Zimmer's $13.4 billion bid for Biomet, concerned that the creation of the world's second-largest orthopedic products group may hurt competition, three people familiar with the matter said on Thursday.
* Zimmer may have to offer concessions to allay EU worries
- Eli Lilly and Co said it would stop the development of its drug to treat the autoimmune disorder lupus, after it was found to be not effective enough in late-stage trials.
BRUSSELS, Oct 2 - EU antitrust regulators will widen a probe into Zimmer Holdings Inc's $13.4 billion bid for Biomet Inc but clear Eli Lilly's offer for a Novartis AG unit, three people familiar with the matter said on Thursday.
Oct 2 - Eli Lilly and Co said it would discontinue the development of its lupus drug as the treatment was not found to be effective enough in two late-stage trials.
|Takeda Pharmaceutical Co Ltd (4502.T)||¥4,538||+52.00|
|Johnson & Johnson (JNJ.N)||$102.63||0.00|
|Pfizer Inc. (PFE.N)||$29.05||+0.45|
|Novartis AG (NOVN.VX)||CHF85.75||+0.35|
|Merck & Co., Inc. (MRK.N)||$56.93||+0.30|
|Abbott Laboratories (ABT.N)||$42.13||-0.30|
|Sanofi SA (SASY.PA)||€84.60||-0.30|
|AstraZeneca plc (AZN.L)||4,327.50p||-7.00|
|GlaxoSmithKline plc (GSK.L)||1,415.50p||+3.50|
|Bristol-Myers Squibb Co (BMY.N)||$53.46||+0.96|
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (LLY). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Thomson Reuters Stock Report
Provider: S&P Capital IQ – STARS Reports
"The Economy Matters" Report for LLY: the economy's impact on LLY's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider: MacroRisk Analytics/EconomicInvestor
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.